Efficacy of Posterior Subtenon Triamcinolone Acetonide Injection with Intravitreal Ranibizumab Injection in Diabetic Macular Edema | ||
| Al-Azhar International Medical Journal | ||
| Volume 2025, Issue 5, May 2025, Pages 114-119 PDF (350.92 K) | ||
| Document Type: Original Article | ||
| DOI: https://doi.org/10.21608/aimj.2025.446563 | ||
| Authors | ||
| Adel Abdelaziz Mahmoud Hasona1; Nehad Mohamed Yusef2; Mohammad Shehata Mohammad Shehata* 3 | ||
| 1Professor of Ophthalmology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt | ||
| 2Lecturer of Ophthalmology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt; | ||
| 3MBBCh, Faculty of Medicine, Al-Azhar University, Cairo, Egypt. | ||
| Abstract | ||
| Background: One of the most prevalent consequences of diabetes is diabetic macular edema (DME), which can cause diabetic retinopathy (DR) and eventually blindness in young people. Aim: To compare subtenon triamcinolone acetonide injection with intravitreal ranibizumab injection in terms of diabetic macular edema (DME). Methods: Two groups were formed from forty eyes of patients with diffuse diabetic macular edema. One group had three intravitreal injections of 0.3 mg of Ranibizumab, administered in 0.05 ml, spaced one month apart. The second group also got injections, but the first one also included a 40mg/ml dose of triamcinolone acetonide administered posteriorly sub-tenon (PST), under normal aseptic techniques in the ophthalmic surgery theater. Pre- and post-injection optical coherence tomography (OCT) measurements of the central subfield macular thickness (CMT) were assessed at different time points. Visual acuity was evaluated by measuring BCVA and intraocular pressure (IOP), as well as any problems linked to these two methods. Results: At the one, two, and three-month marks, the BCVA is much better in the combination group (86.7%, 173.3%, and 206.7%) than in the intravitreal Ranibizumab only group (33.3%, 71.4%, and 76.1%). During the follow-up period, this enhancement was noted in both groups. A significant difference (p<0.001) was found between the two groups with respect to CMT at 2 and 3 months. Conclusions: Regarding enhancing BCVA and decreasing CMT, having the benefits of TA while avoiding risks of intravitreal TA, such as raised IOP, posterior sub-tenon triamcinolone acetonide injection with intravitreal Ranibizumab is an excellent tool for treating diabetic macular edema (DME). | ||
| Keywords | ||
| Diabetic macular edema; Diabetes mellitus; Diabetic retinopathy; Posterior subtenon | ||
|
Statistics Article View: 22 PDF Download: 20 |
||
